[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
N V KhachanovaK Z BakhtiyarovaAlexey BoykoYa V VlasovM V DavydovskayaEvgeniy EvdoshenkoMaria ZakharovaS V KotovE V PopovaStella SivertsevaN A TotolyanF A KhabirovPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2020)
Alemtuzumab (Lemtrada) is a recombinant humanized IgG1 kappa monoclonal antibody to the surface cell glycoprotein, a CD52 differentiation cluster. The drug is approved for use in more than 65 countries, including the Russian Federation. The drug is one of the most effective methods of treating patients with aggressive multiple sclerosis, but the risk management plan should be followed. The safety profile of the drug includes infusion-associated reactions, thyroid dysfunction, immune cytopenia, acute cardiovascular events, infections, and other autoimmune diseases. This publication provides updated practical recommendations for the use of the drug and ensuring the safety of patients treated with alemtuzumab.
Keyphrases
- cardiovascular events
- monoclonal antibody
- multiple sclerosis
- drug induced
- coronary artery disease
- adverse drug
- clinical practice
- low dose
- single cell
- stem cells
- oxidative stress
- cell therapy
- intensive care unit
- mesenchymal stem cells
- respiratory failure
- bone marrow
- inflammatory response
- acute respiratory distress syndrome
- nk cells
- mechanical ventilation